久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Inching toward first-in-class new drugs

By Liu Zhihua | China Daily | Updated: 2020-12-07 09:28
Share
Share - WeChat
[Photo/IC]

When I started reporting on healthcare around 10 year ago, domestic drugs for cancer treatment were often seen as being less effective than foreign medicine.

Since investing in new drug development does not produce instant or even near-term returns and hence is regarded as risky, domestic pharmaceutical companies tended to produce low-end generics, preferring not to develop innovative or original drugs even when there was high demand.

There were thousands of such small or medium-sized firms that focused on generics, active pharmaceutical ingredients and traditional Chinese medicine. However, regulatory reform starting in 2015 proved to be a game-changer.

In August that year, the State Council, China's Cabinet, released a document on reforming the review and approval system for drugs and medical devices, to promote a structural reform of the pharmaceutical industry with an emphasis on drug efficacy, safety and quality.

Over the years, regulators focused on measures that encourage innovation, especially research and development of new drugs in line with global developments, or as per urgent clinical demand, and also to speed up clinical trial registration and new drug reviews, in order to enhance domestic generics and help bring down drug prices.

In 2017, China became a full member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, an organization that standardizes global drug regulations.

As a result, overseas investment in China's healthcare industry and the number of products launched in the China market by multinational companies have been growing. More importantly, domestic pharmaceutical companies also started to gain increasing presence in both domestic and international markets, especially in the biotech sector.

With the domestic market exerting the pressure of demand for high-quality products, local pharmaceutical companies now invest more in innovation and R&D to make high-end generics and innovative drugs. Some of them have been able to conduct world-class R&D of cutting-edge treatments, such as PD-1/PD-L1 inhibitors, anti-CD47 monoclonal antibodies, and other revolutionary cancer therapeutics.

Although none of those drugs are first-in-class, some have the potential to be best-in-class. And thanks to the increasing number of high-quality homegrown drugs, as well as reforms in healthcare system and supportive policies for drug procurement and reimbursement, drug prices have been brought down drastically.

Official data showed there were three rounds of volume-based drug procedure programs so far, which helped cut the average price of 112 drugs by generic name by 54 percent, saving 53.9 billion yuan ($8.2 billion) in medical costs for patients. Increasing digital capacity is another aspect of innovation in China's pharmaceutical industry. Digital giants and other technology players have been creating solutions that can better serve patients as well as meet the needs of physicians.

All this has led to a surge in investments flowing into the industry, as the country's ongoing reforms have been unleashing the potential of the domestic market.

However, despite the local companies' emphasis on increasing R&D capacities, they are still followers of truly breakthrough innovations; they still need to build up innovation capacities and enhance manufacturing technologies to develop and produce first-in-class drugs.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 国产精品久久久久久久久久免费 | 日本免费久久 | 欧美高清在线精品一区二区不卡 | 欧美freesex10一13黑人 | 国产第二页| 手机看片国产在线 | 天海翼精品久久中文字幕 | a级毛片免费观看网站 | 国产黄色一级毛片 | 亚洲精品综合一区二区三区 | 播播网手机在线播放 | 国产一级a毛片高清 | 美女张开腿让男人桶爽动漫视频 | 精品特级一级毛片免费观看 | 久久精品国产99久久99久久久 | 欧美 日韩 国产 成人 在线观看 | freesex日本高清nice | 尤蜜网站在线进入免费 | 黄色网址网站在线观看 | 亚洲国产欧美一区 | 狠狠色丁香婷婷久久综合考虑 | 欧美特黄三级成人 | 中文字幕欧美日韩一 | 国产一区二区在线观看免费 | 北条麻妃在线一区二区 | 女人张开腿 让男人桶视频 女人张开腿等男人桶免费视频 | 免费一区二区三区视频狠狠 | 美女视频大全网站免费 | 免费乱人伦 | 韩国一级片在线观看 | 久久综合精品视频 | 国产成人一区二区三区高清 | 最近手机高清中文字幕大全7 | 日本草草视频在线观看 | 午夜一区二区福利视频在线 | 欧美精品一区二区精品久久 | 免费狼人久久香蕉网 | 男人的天堂毛片 | 一本久道久久综合中文字幕 | 国产草草影院 | 欧美一级高清在线观看 |